{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,15]],"date-time":"2026-06-15T13:29:36Z","timestamp":1781530176518,"version":"3.54.1"},"reference-count":69,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2022,10,1]],"date-time":"2022-10-01T00:00:00Z","timestamp":1664582400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,10,1]],"date-time":"2022-10-01T00:00:00Z","timestamp":1664582400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,9,27]],"date-time":"2023-09-27T00:00:00Z","timestamp":1695772800000},"content-version":"am","delay-in-days":361,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,10,1]],"date-time":"2022-10-01T00:00:00Z","timestamp":1664582400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2022,10,1]],"date-time":"2022-10-01T00:00:00Z","timestamp":1664582400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2022,10,1]],"date-time":"2022-10-01T00:00:00Z","timestamp":1664582400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2022,10,1]],"date-time":"2022-10-01T00:00:00Z","timestamp":1664582400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2022,10,1]],"date-time":"2022-10-01T00:00:00Z","timestamp":1664582400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Pharmacology Biochemistry and Behavior"],"published-print":{"date-parts":[[2022,10]]},"DOI":"10.1016\/j.pbb.2022.173467","type":"journal-article","created":{"date-parts":[[2022,9,22]],"date-time":"2022-09-22T11:57:19Z","timestamp":1663847839000},"page":"173467","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":26,"special_numbering":"C","title":["In vitro and in vivo pharmacology of nine novel synthetic cannabinoid receptor agonists"],"prefix":"10.1016","volume":"220","author":[{"given":"Julie A.","family":"Marusich","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas F.","family":"Gamage","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yanan","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luli R.","family":"Akinfiresoye","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jenny L.","family":"Wiley","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"5","key":"10.1016\/j.pbb.2022.173467_bb0005","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1080\/10408444.2020.1762539","article-title":"The synthetic cannabinoids phenomenon: from structure to toxicological properties. A review","volume":"50","author":"Alves","year":"2020","journal-title":"Crit. Rev. Toxicol."},{"issue":"21","key":"10.1016\/j.pbb.2022.173467_bb0010","doi-asserted-by":"crossref","first-page":"3672","DOI":"10.1021\/acschemneuro.0c00591","article-title":"Exploring stereochemical and conformational requirements at cannabinoid receptors for synthetic cannabinoids related to SDB-006, 5F-SDB-006, CUMYL-PICA, and 5F-CUMYL-PICA","volume":"11","author":"Ametovski","year":"2020","journal-title":"ACS Chem. Neurosci."},{"issue":"1","key":"10.1016\/j.pbb.2022.173467_bb0015","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1016\/j.pnpbp.2011.12.001","article-title":"CB(2): therapeutic target-in-waiting","volume":"38","author":"Atwood","year":"2012","journal-title":"Prog. Neuro-Psychopharmacol. Biol. Psychiatry"},{"issue":"2","key":"10.1016\/j.pbb.2022.173467_bb0020","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1016\/S0376-8716(99)00152-0","article-title":"Influence of the N-1 alkyl chain length of cannabimimetic indoles upon CB(1) and CB(2) receptor binding","volume":"60","author":"Aung","year":"2000","journal-title":"Drug Alcohol Depend."},{"key":"10.1016\/j.pbb.2022.173467_bb0025","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1016\/S0149-7634(05)80051-X","article-title":"\u22069-tetrahydrocannabinol discrimination in rats as a model for cannabis intoxication","volume":"16","author":"Balster","year":"1992","journal-title":"Neurosci. Biobehav. Rev."},{"key":"10.1016\/j.pbb.2022.173467_bb0030","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1007\/164_2018_144","article-title":"The chemistry and pharmacology of synthetic cannabinoid receptor agonist new psychoactive substances: evolution","volume":"252","author":"Banister","year":"2018","journal-title":"Handb. Exp. Pharmacol."},{"key":"10.1016\/j.pbb.2022.173467_bb0035","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1007\/164_2018_143","article-title":"The chemistry and pharmacology of synthetic cannabinoid receptor agonists as new psychoactive substances: origins","volume":"252","author":"Banister","year":"2018","journal-title":"Handb. Exp. Pharmacol."},{"key":"10.1016\/j.pbb.2022.173467_bb0040","doi-asserted-by":"crossref","first-page":"e10","DOI":"10.1016\/j.forsciint.2017.01.020","article-title":"Acute intoxication caused by synthetic cannabinoids 5F-ADB and MMB-2201: a case series","volume":"273","author":"Barcel\u00f3","year":"2017","journal-title":"Forensic Sci. Int."},{"issue":"3","key":"10.1016\/j.pbb.2022.173467_bb0045","doi-asserted-by":"crossref","first-page":"350","DOI":"10.1124\/jpet.113.206003","article-title":"Differential drug-drug interactions of the synthetic cannabinoids JWH-018 and JWH-073: implications for drug abuse liability and pain therapy","volume":"346","author":"Brents","year":"2013","journal-title":"J. Pharmacol. Exp. Ther."},{"issue":"24","key":"10.1016\/j.pbb.2022.173467_bb0050","doi-asserted-by":"crossref","first-page":"4434","DOI":"10.1021\/acschemneuro.0c00644","volume":"11","author":"Cannaert","year":"2020","journal-title":"ACS Chem. Neurosci."},{"key":"10.1016\/j.pbb.2022.173467_bb0055","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1016\/j.drugalcdep.2014.08.005","article-title":"Synthetic cannabinoids: epidemiology, pharmacodynamics, and clinical implications","volume":"144","author":"Castaneto","year":"2014","journal-title":"Drug Alcohol Depend."},{"issue":"2","key":"10.1016\/j.pbb.2022.173467_bb0060","doi-asserted-by":"crossref","first-page":"586","DOI":"10.1016\/S0022-3565(25)12911-X","article-title":"In vivo characterization of a specific cannabinoid receptor antagonist (SR141716A): inhibition of delta 9-tetrahydrocannabinol-induced responses and apparent agonist activity","volume":"277","author":"Compton","year":"1996","journal-title":"J. Pharmacol. Exp. Ther."},{"issue":"5","key":"10.1016\/j.pbb.2022.173467_bb0065","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1007\/s11920-016-0694-1","article-title":"Adverse effects of synthetic cannabinoids: management of acute toxicity and withdrawal","volume":"18","author":"Cooper","year":"2016","journal-title":"Curr. Psychiatry Rep."},{"key":"10.1016\/j.pbb.2022.173467_bb0070","series-title":"Schedules of Controlled Substances: Temporary Placement of 5F-EDMB-PINACA, 5F-MDMB-PICA, FUB-AKB48, 5F-CUMYL-PINACA, and FUB-144 into Schedule I","author":"Drug Enforcement Administration","year":"2019"},{"key":"10.1016\/j.pbb.2022.173467_bb0075","series-title":"2019 National Drug Threat Assessment","author":"Drug Enforcement Administration","year":"2020"},{"key":"10.1016\/j.pbb.2022.173467_bb0080","first-page":"20318","article-title":"Schedules of controlled substances: placement of 5F-EDMB-PINACA, 5FMDMB-PICA, FUB-AKB48, 5F-CUMYLPINACA, and FUB-144 in schedule I","author":"Drug Enforcement Administration","year":"2022","journal-title":"Fed. Regist."},{"issue":"1","key":"10.1016\/j.pbb.2022.173467_bb0085","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1016\/j.lfs.2013.09.017","article-title":"Distinct pharmacology and metabolism of K2 synthetic cannabinoids compared to \u0394(9)-THC: mechanism underlying greater toxicity?","volume":"97","author":"Fantegrossi","year":"2014","journal-title":"Life Sci."},{"key":"10.1016\/j.pbb.2022.173467_bb0090","series-title":"Guidance for Industry: Assessment of Abuse Potential of Drugs","author":"Food and Drug Administration","year":"2010"},{"key":"10.1016\/j.pbb.2022.173467_bb0095","author":"Food and Drug Administration","year":"2020"},{"key":"10.1016\/j.pbb.2022.173467_bb0100","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1016\/j.neuropharm.2017.08.008","article-title":"The great divide: separation between in vitro and in vivo effects of PSNCBAM-based CB(1) receptor allosteric modulators","volume":"125","author":"Gamage","year":"2017","journal-title":"Neuropharmacology"},{"issue":"2","key":"10.1016\/j.pbb.2022.173467_bb0105","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1124\/jpet.117.246983","article-title":"Molecular and behavioral pharmacological characterization of abused synthetic cannabinoids MMB- and MDMB-FUBINACA, MN-18, NNEI, CUMYL-PICA, and 5-fluoro-CUMYL-PICA","volume":"365","author":"Gamage","year":"2018","journal-title":"J. Pharmacol. Exp. Ther."},{"issue":"3","key":"10.1016\/j.pbb.2022.173467_bb0110","doi-asserted-by":"crossref","first-page":"414","DOI":"10.1124\/jpet.118.254425","article-title":"Synthetic cannabinoid hydroxypentyl metabolites retain efficacy at human cannabinoid receptors","volume":"368","author":"Gamage","year":"2019","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"10.1016\/j.pbb.2022.173467_bb0115","doi-asserted-by":"crossref","DOI":"10.1016\/j.pbb.2020.172918","article-title":"In vitro and in vivo pharmacological evaluation of the synthetic cannabinoid receptor agonist EG-018","volume":"193","author":"Gamage","year":"2020","journal-title":"Pharmacol. Biochem. Behav."},{"key":"10.1016\/j.pbb.2022.173467_bb0120","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1016\/j.neuro.2018.11.004","article-title":"Cannabinoid-like effects of five novel carboxamide synthetic cannabinoids","volume":"70","author":"Gatch","year":"2019","journal-title":"Neurotoxicology"},{"issue":"2&3","key":"10.1016\/j.pbb.2022.173467_bb0125","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1097\/FBP.0000000000000618","article-title":"Behavioral pharmacology of five novel synthetic cannabinoids","volume":"33","author":"Gatch","year":"2022","journal-title":"Behav. Pharmacol."},{"issue":"4","key":"10.1016\/j.pbb.2022.173467_bb0130","doi-asserted-by":"crossref","first-page":"924","DOI":"10.1038\/s41386-021-01227-8","article-title":"Structure-activity relationships for 5F-MDMB-PICA and its 5F-pentylindole analogs to induce cannabinoid-like effects in mice","volume":"47","author":"Glatfelter","year":"2022","journal-title":"Neuropsychopharmacology"},{"issue":"2","key":"10.1016\/j.pbb.2022.173467_bb0135","doi-asserted-by":"crossref","first-page":"525","DOI":"10.1038\/sj.bjp.0703827","article-title":"Separation of cannabinoid receptor affinity and efficacy in delta-8- tetrahydrocannabinol side-chain analogues","volume":"132","author":"Griffin","year":"2001","journal-title":"Br. J. Pharmacol."},{"issue":"2","key":"10.1016\/j.pbb.2022.173467_bb0140","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1124\/jpet.116.233163","article-title":"Stratification of cannabinoid 1 receptor (CB1R) agonist efficacy: manipulation of CB1R density through use of transgenic mice reveals congruence between in vivo and in vitro assays","volume":"359","author":"Grim","year":"2016","journal-title":"J. Pharmacol. Exp. Ther."},{"issue":"3","key":"10.1016\/j.pbb.2022.173467_bb0145","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1515\/jbcpp-2015-0118","article-title":"Pharmacological characterization of repeated administration of the first generation abused synthetic cannabinoid CP47,497","volume":"27","author":"Grim","year":"2016","journal-title":"J. Basic Clin. Physiol. Pharmacol."},{"issue":"20","key":"10.1016\/j.pbb.2022.173467_bb0150","doi-asserted-by":"crossref","DOI":"10.3390\/molecules26206190","article-title":"The spicy story of cannabimimetic indoles","volume":"26","author":"Howlett","year":"2021","journal-title":"Molecules"},{"issue":"2","key":"10.1016\/j.pbb.2022.173467_bb0155","doi-asserted-by":"crossref","first-page":"278","DOI":"10.1124\/jpet.117.240572","article-title":"Apparent affinity estimates and reversal of the effects of synthetic cannabinoids AM-2201, CP-47,497, JWH-122, and JWH-250 by rimonabant in rhesus monkeys","volume":"362","author":"Hruba","year":"2017","journal-title":"J. Pharmacol. Exp. Ther."},{"issue":"7","key":"10.1016\/j.pbb.2022.173467_bb0160","doi-asserted-by":"crossref","first-page":"641","DOI":"10.2174\/1389557054368844","article-title":"CB2 receptor ligands","volume":"5","author":"Huffman","year":"2005","journal-title":"Mini Rev. Med. Chem."},{"issue":"4","key":"10.1016\/j.pbb.2022.173467_bb0165","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1016\/S0960-894X(01)80155-4","article-title":"Design, synthesis and pharmacology of cannabimimetic indoles","volume":"4","author":"Huffman","year":"1994","journal-title":"Bioorg. Med. Chem. Lett."},{"issue":"7","key":"10.1016\/j.pbb.2022.173467_bb0170","doi-asserted-by":"crossref","first-page":"1397","DOI":"10.1016\/S0968-0896(02)00649-1","article-title":"Structure-activity relationships for 1',1'-dimethylalkyl-Delta8-tetrahydrocannabinols","volume":"11","author":"Huffman","year":"2003","journal-title":"Bioorg. Med. Chem."},{"issue":"1","key":"10.1016\/j.pbb.2022.173467_bb0175","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1080\/15563650.2021.1928162","article-title":"Clinical symptoms and blood concentration of new psychoactive substances (NPS) in intoxicated and hospitalized patients in the Budapest region of Hungary (2018\u201319)","volume":"60","author":"Instit\u00f3ris","year":"2022","journal-title":"Clin. Toxicol. (Phila.)"},{"key":"10.1016\/j.pbb.2022.173467_bb0180","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1007\/7854_2016_16","article-title":"Tripping with synthetic cannabinoids (\"Spice\"): anecdotal and experimental observations in animals and man","volume":"32","author":"Jarbe","year":"2017","journal-title":"Curr. Top. Behav. Neurosci."},{"issue":"1","key":"10.1016\/j.pbb.2022.173467_bb0185","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1021\/jm9902281","article-title":"QSAR analysis of Delta(8)-THC analogues: relationship of side-chain conformation to cannabinoid receptor affinity and pharmacological potency","volume":"43","author":"Keimowitz","year":"2000","journal-title":"J. Med. Chem."},{"issue":"1","key":"10.1016\/j.pbb.2022.173467_bb0190","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1002\/dta.2698","article-title":"Detection and characterization of the new synthetic cannabinoid APP-BINACA in forensic casework","volume":"12","author":"Krotulski","year":"2020","journal-title":"Drug Test. Anal."},{"key":"10.1016\/j.pbb.2022.173467_bb0195","doi-asserted-by":"crossref","DOI":"10.1016\/j.neuropharm.2021.108800","article-title":"Pharmacokinetics and pharmacodynamics of the synthetic cannabinoid, 5F-MDMB-PICA, in male rats","volume":"199","author":"Krotulski","year":"2021","journal-title":"Neuropharmacology"},{"key":"10.1016\/j.pbb.2022.173467_bb0200","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1016\/j.pbb.2014.01.002","article-title":"Evaluation of WIN 55,212\u20132 self-administration in rats as a potential cannabinoid abuse liability model","volume":"118","author":"Lefever","year":"2014","journal-title":"Pharmacol. Biochem. Behav."},{"issue":"3","key":"10.1016\/j.pbb.2022.173467_bb0205","doi-asserted-by":"crossref","first-page":"187","DOI":"10.2174\/156802608783498014","article-title":"Recent advances in the development of selective ligands for the cannabinoid CB(2) receptor","volume":"8","author":"Marriott","year":"2008","journal-title":"Curr. Top. Med. Chem."},{"key":"10.1016\/j.pbb.2022.173467_bb0210","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1016\/j.pbb.2014.05.010","article-title":"In vivo effects of synthetic cannabinoids JWH-018 and JWH-073 and phytocannabinoid \u03949-THC in mice: inhalation versus intraperitoneal injection","volume":"124","author":"Marshell","year":"2014","journal-title":"Pharmacol. Biochem. Behav."},{"issue":"3","key":"10.1016\/j.pbb.2022.173467_bb0215","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1016\/0376-8716(94)01081-U","article-title":"Pharmacological evaluation of dimethylheptyl analogs of delta 9-THC: reassessment of the putative three-point cannabinoid-receptor interaction","volume":"37","author":"Martin","year":"1995","journal-title":"Drug Alcohol Depend."},{"issue":"3","key":"10.1016\/j.pbb.2022.173467_bb0220","doi-asserted-by":"crossref","first-page":"1065","DOI":"10.1016\/S0022-3565(24)35007-4","article-title":"Manipulation of the tetrahydrocannabinol side chain delineates agonists, partial agonists, and antagonists","volume":"290","author":"Martin","year":"1999","journal-title":"J. Pharmacol. Exp. Ther."},{"issue":"Pt A","key":"10.1016\/j.pbb.2022.173467_bb0225","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1016\/j.neuropharm.2017.10.041","article-title":"Finding order in chemical chaos - continuing characterization of synthetic cannabinoid receptor agonists","volume":"134","author":"Marusich","year":"2018","journal-title":"Neuropharmacology"},{"key":"10.1016\/j.pbb.2022.173467_bb0230","series-title":"Guide for the Care and Use of Laboratory Animals","year":"2011"},{"key":"10.1016\/j.pbb.2022.173467_bb0235","doi-asserted-by":"crossref","DOI":"10.1016\/j.bcp.2020.113871","article-title":"Signalling profiles of a structurally diverse panel of synthetic cannabinoid receptor agonists","volume":"175","author":"Patel","year":"2020","journal-title":"Biochem. Pharmacol."},{"issue":"2","key":"10.1016\/j.pbb.2022.173467_bb0240","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1016\/S0163-7258(97)82001-3","article-title":"Pharmacology of cannabinoid CB1 and CB2 receptors","volume":"74","author":"Pertwee","year":"1997","journal-title":"Pharmacol. Ther."},{"issue":"7","key":"10.1016\/j.pbb.2022.173467_bb0245","doi-asserted-by":"crossref","first-page":"1383","DOI":"10.1002\/dta.3037","volume":"13","author":"Pike","year":"2021","journal-title":"Drug Test. Anal."},{"issue":"2","key":"10.1016\/j.pbb.2022.173467_bb0250","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1080\/15563650.2019.1661425","article-title":"Synthetic cannabinoid receptor agonists: classification and nomenclature","volume":"58","author":"Potts","year":"2020","journal-title":"Clin. Toxicol. (Phila.)"},{"issue":"5","key":"10.1016\/j.pbb.2022.173467_bb0255","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1517\/13543776.2012.682570","article-title":"Selective cannabinoid receptor 2 modulators: a patent review 2009\u2013present","volume":"22","author":"Riether","year":"2012","journal-title":"Expert Opin. Ther. Pat."},{"issue":"24","key":"10.1016\/j.pbb.2022.173467_bb0260","doi-asserted-by":"crossref","first-page":"4653","DOI":"10.1111\/bph.14829","article-title":"In vitro determination of the efficacy of illicit synthetic cannabinoids at CB1 receptors","volume":"176","author":"Sachdev","year":"2019","journal-title":"Br. J. Pharmacol."},{"issue":"3","key":"10.1016\/j.pbb.2022.173467_bb0265","doi-asserted-by":"crossref","first-page":"989","DOI":"10.1016\/S0022-3565(25)20744-3","article-title":"Evaluation of binding in a transfected cell line expressing a peripheral cannabinoid receptor (CB2): identification of cannabinoid receptor subtype selective ligands","volume":"278","author":"Showalter","year":"1996","journal-title":"J. Pharmacol. Exp. Ther."},{"issue":"2","key":"10.1016\/j.pbb.2022.173467_bb0270","doi-asserted-by":"crossref","first-page":"156","DOI":"10.1039\/D1MD00242B","article-title":"Structure-activity relationships of valine, tert-leucine, and phenylalanine amino acid-derived synthetic cannabinoid receptor agonists related to ADB-BUTINACA, APP-BUTINACA, and ADB-P7AICA","volume":"13","author":"Sparkes","year":"2022","journal-title":"RSC Med. Chem."},{"key":"10.1016\/j.pbb.2022.173467_bb0275","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1007\/7854_2016_60","article-title":"Pharmacological and toxicological effects of synthetic cannabinoids and their metabolites","volume":"32","author":"Tai","year":"2017","journal-title":"Curr. Top. Behav. Neurosci."},{"issue":"1","key":"10.1016\/j.pbb.2022.173467_bb0280","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1124\/jpet.116.238717","article-title":"Thermolytic degradation of synthetic cannabinoids: chemical exposures and pharmacological consequences","volume":"361","author":"Thomas","year":"2017","journal-title":"J. Pharmacol. Exp. Ther."},{"issue":"1","key":"10.1016\/j.pbb.2022.173467_bb0285","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1002\/dta.2688","article-title":"5F-MDMB-PICA metabolite identification and cannabinoid receptor activity","volume":"12","author":"Truver","year":"2020","journal-title":"Drug Test. Anal."},{"key":"10.1016\/j.pbb.2022.173467_bb0290","series-title":"Current NPS Threats Volume II","year":"2020"},{"issue":"8","key":"10.1016\/j.pbb.2022.173467_bb0295","doi-asserted-by":"crossref","first-page":"1350","DOI":"10.1002\/dta.3263","article-title":"NPS detection in prison: a systematic literature review of use, drug form, and analytical approaches","volume":"14","author":"Vaccaro","year":"2022","journal-title":"Drug Test. Anal."},{"issue":"1\u20133","key":"10.1016\/j.pbb.2022.173467_bb0300","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1016\/j.ejphar.2009.05.010","article-title":"Discriminative stimulus properties of delta9-tetrahydrocannabinol (THC) in C57Bl\/6J mice","volume":"615","author":"Vann","year":"2009","journal-title":"Eur. J. Pharmacol."},{"issue":"1","key":"10.1016\/j.pbb.2022.173467_bb0305","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/S0022-3565(25)12022-3","article-title":"Antagonism of the discriminative stimulus effects of delta 9-tetrahydrocannabinol in rats and rhesus monkeys","volume":"275","author":"Wiley","year":"1995","journal-title":"J. Pharmacol. Exp. Ther."},{"issue":"3","key":"10.1016\/j.pbb.2022.173467_bb0310","doi-asserted-by":"crossref","first-page":"995","DOI":"10.1016\/S0022-3565(24)37496-8","article-title":"Structure-activity relationships of indole- and pyrrole-derived cannabinoids","volume":"285","author":"Wiley","year":"1998","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"10.1016\/j.pbb.2022.173467_bb0315","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1016\/j.neuropharm.2013.07.022","article-title":"Cannabinoids in disguise: Delta9-tetrahydrocannabinol-like effects of tetramethylcyclopropyl ketone indoles","volume":"75","author":"Wiley","year":"2013","journal-title":"Neuropharmacology"},{"issue":"1","key":"10.1016\/j.pbb.2022.173467_bb0320","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1016\/j.lfs.2013.09.011","article-title":"Moving around the molecule: relationship between chemical structure and in vivo activity of synthetic cannabinoids","volume":"97","author":"Wiley","year":"2014","journal-title":"Life Sci."},{"issue":"3","key":"10.1016\/j.pbb.2022.173467_bb0325","doi-asserted-by":"crossref","first-page":"328","DOI":"10.1124\/jpet.115.225326","article-title":"AB-CHMINACA, AB-PINACA, and FUBIMINA: affinity and potency of novel synthetic cannabinoids in producing Delta9-tetrahydrocannabinol-like effects in mice","volume":"354","author":"Wiley","year":"2015","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"10.1016\/j.pbb.2022.173467_bb0330","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1016\/j.drugalcdep.2016.11.035","article-title":"Comparison of the discriminative stimulus and response rate effects of Delta9-tetrahydrocannabinol and synthetic cannabinoids in female and male rats","volume":"172","author":"Wiley","year":"2017","journal-title":"Drug Alcohol Depend."},{"key":"10.1016\/j.pbb.2022.173467_bb0335","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1007\/7854_2016_17","article-title":"Combination chemistry: structure-activity relationships of novel psychoactive cannabinoids","volume":"32","author":"Wiley","year":"2017","journal-title":"Curr. Top. Behav. Neurosci."},{"key":"10.1016\/j.pbb.2022.173467_bb0340","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1016\/j.neuro.2019.04.002","article-title":"Do you feel it now? Route of administration and Delta(9)-tetrahydrocannabinol-like discriminative stimulus effects of synthetic cannabinoids in mice","volume":"73","author":"Wiley","year":"2019","journal-title":"Neurotoxicology"},{"key":"10.1016\/j.pbb.2022.173467_bb0345","doi-asserted-by":"crossref","DOI":"10.1016\/j.pnpbp.2020.110064","article-title":"Sex, species and age: effects of rodent demographics on the pharmacology of \u2206(9)-tetrahydrocanabinol","volume":"106","author":"Wiley","year":"2021","journal-title":"Prog. Neuro-Psychopharmacol. Biol. Psychiatry"}],"container-title":["Pharmacology Biochemistry and Behavior"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0091305722001460?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0091305722001460?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,25]],"date-time":"2025-09-25T04:43:32Z","timestamp":1758775412000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0091305722001460"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,10]]},"references-count":69,"alternative-id":["S0091305722001460"],"URL":"https:\/\/doi.org\/10.1016\/j.pbb.2022.173467","relation":{},"ISSN":["0091-3057"],"issn-type":[{"value":"0091-3057","type":"print"}],"subject":[],"published":{"date-parts":[[2022,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"In vitro and in vivo pharmacology of nine novel synthetic cannabinoid receptor agonists","name":"articletitle","label":"Article Title"},{"value":"Pharmacology Biochemistry and Behavior","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.pbb.2022.173467","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"173467"}}